Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hummel, Margit [VerfasserIn]   i
 Buchheidt, Dieter [VerfasserIn]   i
 Reiter, Sebastian [VerfasserIn]   i
 Bergmann, Jörg [VerfasserIn]   i
 Adam, Katja [VerfasserIn]   i
 Hehlmann, Rüdiger [VerfasserIn]   i
Titel:Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase
Verf.angabe:Margit Hummel, Dieter Buchheidt, Sebastian Reiter, Jörg Bergmann, Katja Adam, Rüdiger Hehlmann
E-Jahr:2005
Jahr:10 November 2005
Umfang:4 S.
Fussnoten:Gesehen am 11.05.2022
Titel Quelle:Enthalten in: European journal of haematology
Ort Quelle:Oxford : Wiley-Blackwell, 1987
Jahr Quelle:2005
Band/Heft Quelle:75(2005), 6, Seite 518-521
ISSN Quelle:1600-0609
Abstract:Abstract: Introduction: Rasburicase is a recombinant urate oxidase that is produced by a genetically modified Saccharomyces cerevisiae and has been approved for prophylaxis and treatment of tumor lysis syndrome in 2001. In several studies, rasburicase, given at a dose of 0.15-0.2 mg/kg for up to 7 d, proved to be highly effective in lowering urate levels. Case report: We report the case of a patient with chronic lymphatic leukemia (CLL) who experienced tumor lysis syndrome (TLS) with acute renal failure after fludarabine/cyclophosphamide chemotherapy and after bendamustine treatment. During the first episode of TLS, after fludarabine/cyclophosphamide (creatinine 3.3 mg/dL, urate 24.6 mg/dL), the patient received rasburicase 0.2 mg/kg for 3 d. Urate levels decreased below the lower limit of normal and renal function recovered. After bendamustine therapy, given for disease progression 8 months later, TLS with acute oliguric renal failure re-occurred (creatinine 3.1 mg/dL, urate 20.8 mg/dL). The patient was treated with hyperhydration and two doses of rasburicase (0.056 mg/kg), resulting in a prompt decrease of the urate level and recovery of renal function. Both episodes of TLS were successfully treated with rasburicase in a lower dose than recommended by the manufacturer. During a second bendamustine course, TLS was successfully treated by low doses of rasburicase (0.056 mg/kg for 2 d). Conclusion: This is the first report of TLS in CLL after bendamustine chemotherapy reported in the literature. Treatment and prevention of TLS by low doses of rasburicase is possible and cost-effective.
DOI:doi:10.1111/j.1600-0609.2005.00550.x
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1111/j.1600-0609.2005.00550.x
 Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0609.2005.00550.x
 DOI: https://doi.org/10.1111/j.1600-0609.2005.00550.x
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:chronic lymphocytic leukemia
 hyperuricemia
 rasburicase
 renal failure
 tumor lysis syndrome
 urate oxidase
K10plus-PPN:1801387516
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68917262   QR-Code
zum Seitenanfang